MD

Business Context and Reporting Period

Company: Pediatrix Medical Group, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2005
Business Overview: The Company operates as a management company for pediatric medical practices, including neonatal intensive care and maternal-fetal medicine. It manages affiliated professional contractors that provide physician services in various states and Puerto Rico.

Key Financial Metrics

Operating Margin: 17.9% (Q1 2005) vs. 23.0% (Q1 2004).
Effective Tax Rate: 37.25%.

Material Changes vs. Prior Period

• Revenue Growth: Net patient service revenue increased 10.8% ($16.1 million). Approximately 62.7% of this increase was attributable to acquisitions completed in 2004 and 2005. Same-unit revenue grew 4.0%.
• Expense Increases:
  • Practice Salaries: Increased 13.1% ($11.3 million) due to new staff for acquisitions and volume growth.
  • General & Administrative (G&A): Increased 41.7% ($8.3 million). This spike was primarily driven by a $6.0 million increase in reserves for pending government investigations (Medicaid/TRICARE).
• Profitability Decline: Net income decreased 15.6% ($3.3 million). The decline is largely attributed to the $6.0 million reserve adjustment (approx. $3.8 million after-tax impact) related to the settlement offer for government investigations.
• Cash Flow: Net cash provided by operating activities improved to $656,000 from a use of $7.9 million in the prior year. This improvement was due to better collections (DSO decreased from 61.6 to 57.8 days) and timing of tax payments, offset by significant payments for physician incentives and 401(k) matches.
• Acquisitions: The Company acquired five physician group practices for approximately $36.9 million in cash during the quarter.

Guidance, Outlook, Risks, and Contingencies

• Government Investigations: The Company is subject to ongoing investigations by the FTC regarding competition issues and by federal/state authorities regarding Medicaid and TRICARE billing practices. A $6.0 million reserve was added in Q1 2005 following a settlement offer. Management cannot predict the final outcome or if losses will exceed current reserves.
• Legal Proceedings: The Company faces routine medical malpractice claims and indemnification obligations to hospitals. While management does not expect a material adverse effect, unfavorable resolutions could impact financial results.
• Liquidity: The Company increased its revolving line of credit commitment from $150 million to $225 million in March 2005. Outstanding borrowings were $82.0 million. Management believes current resources are sufficient for the next 12 months.
• Accounting Changes: The Company will adopt FAS 123R (Share-Based Payment) effective January 1, 2006, which will require expensing stock-based compensation, significantly impacting future reported results.
• Subsequent Events: Two additional physician group practices were acquired for $18.2 million after the period end.

Investor Verification Checklist

• Investigation Reserves: Verify the sufficiency of the $6.0 million reserve for Medicaid/TRICARE investigations and the likelihood of additional charges.
• Acquisition Integration: Assess the revenue contribution and profitability of the five practices acquired in Q1 2005 and the two acquired subsequently.
• Debt Covenants: Confirm continued compliance with the $225 million line of credit covenants, particularly net worth requirements.
• Payor Mix: Monitor the shift toward government-sponsored programs, which lowers reimbursement rates and increases contractual adjustments.
• FAS 123R Impact: Review the projected impact of the upcoming stock-based compensation accounting change on 2006 earnings.